Diagnostic Imaging

9
Pipeline Programs
3
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Guerbet
GuerbetFrance - Villepinte
2 programs
2
IobitridolPhase 41 trial
XenetixPhase 41 trial
Active Trials
NCT00382317CompletedEst. Feb 2008
NCT00347022Completed145Est. Jun 2009
Life Molecular Imaging
Life Molecular ImagingGermany - Berlin
6 programs
6
BAY1006578Phase 11 trial
BAY1075553Phase 11 trial
BAY86-9596Phase 11 trial
BAY86-9596Phase 11 trial
BAY94-9392Phase 11 trial
+1 more programs
Active Trials
NCT01153607CompletedEst. Oct 2011
NCT01287845CompletedEst. Nov 2011
NCT01089998CompletedEst. Sep 2011
+3 more trials
Bayer
BayerLEVERKUSEN, Germany
1 program
1
BAY86-4367Phase 11 trial
Active Trials
NCT00975299Terminated16Est. Oct 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GuerbetIobitridol
GuerbetXenetix
Life Molecular ImagingBAY86-9596
Life Molecular ImagingBAY1075553
Life Molecular ImagingBombesin
Life Molecular ImagingBAY1006578
Life Molecular ImagingBAY86-9596
Life Molecular ImagingBAY94-9392
BayerBAY86-4367

Clinical Trials (9)

Total enrollment: 161 patients across 9 trials

A Clinical Study of Iobitridol in Patients Undergoing Multislice Computed Tomography (CT) Abdominal Angiography

Start: Aug 2006Est. completion: Feb 2008
Phase 4Completed

A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications

Start: May 2006Est. completion: Jun 2009145 patients
Phase 4Completed

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

Start: May 2011Est. completion: Dec 2011
Phase 1Completed

PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers

Start: Feb 2011Est. completion: Nov 2011
Phase 1Completed

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers

Start: Nov 2010Est. completion: Dec 2011
Phase 1Completed

Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers

Start: Jun 2010Est. completion: Oct 2011
Phase 1Completed

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations

Start: May 2010Est. completion: Sep 2011
Phase 1Completed

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

Start: Apr 2010Est. completion: Aug 2011
Phase 1Completed

Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers

Start: Sep 2009Est. completion: Oct 201016 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space